Arcturus Therapeutics (ARCT) had a challenging fourth quarter, with revenue and earnings falling short of analyst ...

The European Commission (EC) has approved CSL and Arcturus Therapeutics’ COVID-19 vaccine Kostaive (ARCT-154) for use in individuals aged 18 years and older. The decision follows a recent ...

Arcturus Therapeutics and CSL's COVID-19 vaccine Kostaive has been approved ... 1 subtype of Omicron variant BA.2.86, which is still one of the main strains currently circulating in Europe.

CSL (CSLLY) and Arcturus Therapeutics (ARCT) announced that the European Commission has granted marketing authorization for Kostaive, a self-amplifying mRNA COVID-19 vaccine, for individuals 18 ...

Arcturus received approval from the European Commission (EC) in February for KOSTAIVE, the world’s first approved sa-mRNA COVID-19 vaccine. The centralized marketing authorization of KOSTAIVE ...

CEO of Arcturus. "This approval highlights the clinical promise of KOSTAIVE and its ability to protect against the ever-changing COVID-19 virus." ...

CEO of Arcturus. "This approval highlights the clinical promise of KOSTAIVE and its ability to protect against the ever-changing COVID-19 virus." About sa-mRNA mRNA vaccines help protect against ...

CEO of Arcturus. "This approval highlights the clinical promise of KOSTAIVE and its ability to protect against the ever-changing COVID-19 virus." About sa-mRNAmRNA vaccines help protect against ...

As COVID-19 ... virus variants, the likelihood of optimizing KOSTAIVE's formulation and completing technical enhancements, and the impact of general business and economic conditions. Arcturus ...